The study, published in BMC Endocrine Disorders, followed 108 Chinese men with prolactinoma who received dopamine agonist monotherapy and were tracked for more than a year at the single tertiary center. The mean age at diagnosis was 41.8 years, with a wide spread of roughly 15 years on either side. The disease burden at baseline was striking: the median starting prolactin concentration was 1,039 nanograms per milliliter, orders of magnitude above the normal range, and the median tumor volume was about 2,710 cubic millimeters. Nearly 77 percent of the men had macroadenomas, tumors large enough to be clearly visible and potentially compress surrounding structures, while only about 23 percent had smaller microadenomas. This skew toward advanced disease reflects a well-recognized pattern in male prolactinoma, where symptoms such as reduced libido, erectile dysfunction, and headaches are often dismissed or attributed to other causes until the tumor has grown substantially.

Over a mean follow-up of 2.84 years, the treatment worked remarkably well by most conventional standards. Prolactin levels normalized in 69.4 percent of patients, tumor volume shrank by at least half in 79.6 percent, and 54.6 percent achieved both prolactin normalization and recovery of testosterone, the key hormone of the male gonadal axis. In ten patients the tumor disappeared entirely on imaging — an outcome that was far more common in men with microadenomas, where complete disappearance occurred in 28 percent of cases, compared with just 3.6 percent of macroadenomas. That difference, statistically significant at P equals 0.001, underscores how much the starting tumor size shapes what patients can ultimately expect from medication alone.

But the headline numbers conceal the study’s central insight. When the researchers integrated prolactin control and tumor shrinkage into a single combined classification, they found that discordant responses were common. At the last follow-up, 56.5 percent of the men met the criteria for a good response — normal prolactin plus at least 50 percent tumor-volume reduction — while 36.1 percent fell into a partial response category, meaning one measure improved while the other lagged. Some men normalized their prolactin yet retained bulky residual tumors; others saw dramatic shrinkage while the hormone remained stubbornly elevated. Only 7.4 percent had a poor response, with neither prolactin control nor meaningful tumor reduction. In other words, more than a third of patients would have been misclassified by a single-endpoint assessment.

To move beyond static snapshots, the team built what they call a dynamic integrated response framework, evaluating patients at baseline, at three months, and at one year, and asking which measurements at each stage best predicted the final outcome. The statistical machinery behind this included group comparisons, stage-specific logistic regression, receiver-operating-characteristic analysis to identify cutoff values, and bootstrap internal validation to test the robustness of the models. Sensitivity analyses were used to confirm that the findings were not driven by particular subgroups or analytic choices. The result is a time-stamped map of treatment response rather than a single verdict rendered at the end of follow-up.

The predictors that emerged differed sharply by stage. At baseline, the only significant independent predictor of a final good response was body mass index: lower BMI was associated with better outcomes, with an odds ratio of 0.810 per unit increase in BMI. Why body weight should matter remains an open question, but the association hints at metabolic influences on dopamine agonist sensitivity or on tumor biology itself. By three months, the picture shifted to treatment dynamics: each 10 percent greater reduction in prolactin at that early checkpoint nearly tripled the odds of a final good response, with an odds ratio of 3.093. This suggests that the first three months of therapy are a critical window in which the tumor’s behavior reveals its long-term trajectory.

At the one-year mark, two factors independently predicted a good final response. Prolactin normalization by then carried an odds ratio of 17.712 — a very strong signal — while each additional 10 percent of tumor-volume reduction added a more modest but still significant benefit, with an odds ratio of 1.106. The receiver-operating-characteristic analysis translated these associations into practical exploratory thresholds: a prolactin reduction of at least 94.8 percent at three months, and an absolute prolactin level at or below 23.30 nanograms per milliliter at one year, best separated patients destined for good responses from the rest. These cutoffs are exploratory and require external validation, but they offer clinicians concrete numbers to watch at defined moments in follow-up.

The clinical implications are potentially far-reaching. Current guidelines for managing prolactinoma largely assess treatment success through individual endpoints, and a patient whose prolactin has normalized might be considered a treatment success even if a large tumor mass persists and continues to threaten vision or pituitary function. Conversely, a patient with marked tumor shrinkage but persistently elevated prolactin might be labeled a failure despite clear radiological benefit. The integrated framework distinguishes transitional partial responses — patients still moving toward full control — from persistent ones, allowing clinicians to intensify monitoring, adjust drug doses, or consider surgery or radiotherapy at the right time rather than too late. The authors emphasize that the framework is a candidate endpoint structure for future validation studies, not a finished clinical tool.

Several caveats temper the enthusiasm. The study was retrospective and drawn from a single center, which limits generalizability and leaves open the possibility of selection effects; patients who required surgery or radiotherapy during follow-up were excluded, which may have removed the most treatment-resistant cases from the analysis. The cohort was exclusively male and exclusively Chinese, and prolactinoma behavior and drug tolerance can vary across populations. The response classification, while logically constructed, is new and has not yet been tested prospectively or in independent cohorts. Still, the size of the cohort — 108 men followed for nearly three years on average — is unusual for a disease that is rare in men, and the internal validation strengthens confidence in the identified predictors.

For patients, the takeaway is cautiously optimistic. Dopamine agonist monotherapy achieved high rates of both biochemical and structural control across all tumor sizes in this cohort, confirming that pills alone can do the heavy lifting for most men with prolactinoma, even those presenting with large tumors and prolactin levels a thousand times above normal. For clinicians, the study argues for a more nuanced follow-up rhythm: check prolactin and MRI early, watch the trajectory rather than the snapshot, and recognize that a discordant response is not a contradiction but a distinct clinical state deserving its own management strategy. As endocrinology moves toward personalized, time-dependent assessment of chronic endocrine diseases, this integrated response framework offers a template that could extend well beyond prolactinoma — provided that future prospective studies confirm what this Shanghai cohort has revealed.

Subject of Research: Dopamine agonist monotherapy outcomes in men with prolactinoma

Article Title: Dynamic integrated response to dopamine agonist monotherapy in Chinese men with prolactinoma: a retrospective cohort study

Article References: Zheng, H., Hu, B., Xie, Y., Qu, X., Zhang, S., Ye, H., Li, Y., Lu, R., & Ji, L. (2026). Dynamic integrated response to dopamine agonist monotherapy in Chinese men with prolactinoma: a retrospective cohort study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02636-w

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02636-w

Keywords: prolactinoma, dopamine agonist, prolactin, testosterone, pituitary adenoma, tumor volume, endocrinology, retrospective cohort, treatment response, BMI, macroadenoma, hormonal therapy

The central question was deceptively simple: does the amount of tumor DNA floating in a patient’s plasma actually mirror what radiologists see on a scan? The answer, according to the analysis led by Isabel Heidrich, with Klaus Pantel and Christoffer Gebhardt as senior authors, is a qualified yes. Circulating tumor DNA levels rose and fell in broad agreement with disease status, increasing significantly as radiologic response worsened across the standard RECIST 1.1 categories, from complete remission through partial remission and stable disease to progression. The statistical association was modest but real, with a Spearman correlation coefficient of 0.31 and a p-value of 0.002 across 99 paired time points.

Yet the study’s most valuable contribution may be its honest accounting of where that agreement breaks down. When the researchers tested how well a single ctDNA measurement could identify progressive disease, the discriminative performance was only moderate, yielding an area under the receiver operating characteristic curve of 0.69. Threshold analyses exposed a fundamental trade-off that clinicians will recognize immediately. Setting the bar high, at 25 or more mutant molecules per milliliter of plasma, produced strong specificity of at least 83 percent but sensitivity of no more than 30 percent, meaning the test rarely cried wolf but also missed most progressing patients. Lower thresholds of one to two mutant molecules per milliliter hovered around 56 percent for both sensitivity and specificity, a level of accuracy that cannot stand alone.

To move beyond categorical imaging readouts, the team also compared ctDNA concentrations directly with total metastatic tumor volume, calculated quantitatively rather than judged by eye. Here the correlation was stronger: ctDNA levels tracked tumor volume with a Spearman coefficient of 0.46, highly significant at p less than 0.0001 across 73 paired time points. Crucially, timing mattered. When blood draws and imaging occurred within 30 days of each other, the correlation tightened to 0.56, while measurements separated by longer intervals showed weaker agreement. This temporal effect carries a practical lesson for clinical trials and routine care alike: a ctDNA result is most informative about tumor burden when it is anchored closely in time to an imaging reference point.

Perhaps the most striking finding, however, concerned change itself. If ctDNA is a faithful liquid biopsy of tumor dynamics, then a rise or fall in plasma DNA should parallel a corresponding change in tumor volume. It did not. Dynamic changes in ctDNA were not significantly correlated with changes in tumor volume, with a correlation coefficient of just 0.20 and a p-value of 0.25. In other words, a patient whose ctDNA dropped sharply was not reliably the patient whose tumors shrank the most. This decoupling of trajectories suggests that ctDNA shedding is governed by biology that a ruler on a scan cannot see, including cell death rates, vascularization, and the metabolic state of individual metastases.

That spatial dimension emerged forcefully from the organ-specific analyses. The strength of the association between ctDNA and tumor burden varied dramatically depending on where the metastases were located. Lymph node and peritoneal metastases showed comparatively strong relationships between ctDNA levels and disease status, while lung, liver, and brain metastases contributed far less detectable DNA to the bloodstream. This pattern of differential shedding has direct clinical implications: a patient whose disease is confined to visceral sites may have undetectable ctDNA despite substantial tumor burden, while another with bulky nodal disease may show abundant plasma DNA. A negative blood test, the study suggests, cannot be interpreted without knowing the anatomy of the disease it is meant to represent.

The researchers also quantified how often ctDNA dynamics and radiologic assessments actually agreed. Concordance was high among patients whose disease was clearly responding, reaching 85 percent in those with complete or partial remission. In stable or progressive disease, agreement fell to 72.9 percent. The discordant cases, rather than being dismissed as noise, were examined descriptively and linked to three plausible culprits: tumor heterogeneity within and across metastatic sites, differences in the timing between blood draws and scans, and treatment-related factors that may alter shedding independently of tumor cell numbers. Immune checkpoint inhibitors, which unleash immune cells to attack tumors, may cause inflammatory swelling or delayed shrinkage that complicates both imaging and biomarker readouts in the early weeks of therapy.

Technically, the study relied on a UMI-based amplicon next-generation sequencing assay capable of detecting mutations in BRAF, EGFR, KRAS, NRAS, and PIK3CA. Unique molecular identifiers allow the sequencing platform to distinguish true mutant fragments from errors introduced during amplification, a critical safeguard when hunting for a handful of mutant molecules in a sea of healthy cell-free DNA. By quantifying ctDNA as mutant molecules per milliliter rather than as a binary positive-or-negative call, the assay enabled the continuous, high-frequency sampling that made the temporal analyses possible. The retrospective design and the modest cohort size of 42 patients mean the findings should be validated prospectively, but the density of sampling, 241 time points, gives the conclusions a robustness that sparse datasets cannot match.

What emerges from the combined analysis is neither a triumph for liquid biopsy nor a rebuttal of it, but a map of its boundaries. ctDNA clearly reflects radiologic disease status and overall tumor burden, and its correlation with volume strengthens when measurements are temporally aligned. At the same time, the moderate discrimination of progression, the weak link between ctDNA dynamics and volume changes, and the pronounced heterogeneity of shedding across metastatic sites all argue against replacing scans with blood tests. Instead, the authors position ctDNA as a complementary biomarker, one that adds a molecular, real-time layer to the anatomical snapshot provided by CT and MRI. For a disease like advanced melanoma, where immunotherapy can produce deep and durable responses in some lesions while others escape, that layered view may be exactly what clinicians need to catch relapse earlier and tailor treatment with greater confidence.

Subject of Research: Longitudinal ctDNA monitoring and its relationship to radiologic response and tumor volume in advanced melanoma

Article Title: Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma

Article References: Heidrich, I., Streckenbach, A., Rautmann, C., Freiberg, H., Kött, J., Geidel, G., Rünger, A., Zell, T., Roeper, C., Hansen-Abeck, I., Abeck, F., Schneider, S. W., Smit, D. J., Pantel, K., & Gebhardt, C. (2026). Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma. Journal of Translational Medicine, 24(1), Article 1199. https://doi.org/10.1186/s12967-026-08899-0

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08899-0

Keywords: ctDNA, liquid biopsy, advanced melanoma, immune checkpoint inhibitors, tumor volume, RECIST, tumor heterogeneity, next-generation sequencing, radiologic response, longitudinal monitoring, metastasis, biomarker